• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron

Regeneron scraps Eylea combo therapy after disappointing early trial results

November 29, 2017 By Fink Densford

Regeneron

Regeneron (NSDQ:REGN) is scrapping plans for a new combination drug pairing its Eylea with angiopoietin2 antibody nesvacumab after disappointing results from mid-stage clinical trials, according to a press release it published on Monday. Regeneron received results from 2 Phase 2 trials, the Ruby and Onyx studies, which reported that the combination drug “did not provide sufficient differentiation […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug

September 11, 2017 By Sarah Faulkner

Regeneron, Sanofi

Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma. The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Regeneron, Sanofi-Aventis

Novartis trial results could spell trouble for Regeneron

June 21, 2017 By Sarah Faulkner

Novartis

Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN). Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies. The trials showed […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Novartis, Regeneron, Roche

Regeneron posts mixed Q1 results, Eylea growth slows

May 4, 2017 By Sarah Faulkner

Regeneron

Shares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results. The company’s total sales rose to $1.32 billion, exceeding analysts’ estimate of $1.30 billion. Regeneron’s bottom line jumped 37% to $248.9 million. Adjusted to exclude 1-time items, earnings per share were $2.92, which missed analysts’ […]

Filed Under: Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

Alnylam, The Medicines Co., detail Phase III trial for RNA-based heart drug

April 26, 2017 By Sarah Faulkner

anatomical heart

The Medicines Co. (NSDQ:MDCO) and Alnylam Pharmaceuticals (NSDQ:ALNY) said today that they’ve reached a deal with the FDA over a Phase III trial for the companies’ RNA-based cholesterol-lowering drug, inclisiran. If approved, it would be the 1st RNA-interference therapy on the market. The drug is a part of a new group of drugs called PCSK9 […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Alnylam Pharmaceuticals, Amgen, Regeneron, The Medicines Co.

Sanofi, Regeneron win FDA nod for once-monthly cholesterol injection

April 25, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) said today that the FDA approved the companies’ new supplemental Biologics License Application for a once-monthly, 300 milligram dose of Praluent as a treatment for adults with high low-density lipoprotein cholesterol. The 300 milligram dose is administered using 2 pre-filled pens that each deliver 150 milligrams at an injection site. The […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Regeneron, Sanofi-Aventis

Report: Pharma relies on price hikes for growth

April 25, 2017 By Sarah Faulkner

Prescription drugs

Despite growing pressure from lawmakers over the pharmaceutical industry’s pricey products, new research shows that pharma relied largely on price hikes for growth in 2016. A 120-page report from Credit Suisse demonstrated that net price growth made up 100% of net income growth for a variety of companies within the industry, including Biogen (NSDQ:BIIB), Eli Lilly […]

Filed Under: Featured, Pharmaceuticals, Policy Tagged With: Allergan, Biogen Idec, Eli Lilly & Co., Novo Nordisk, Regeneron

Pharma execs assess landscape under President Trump

December 2, 2016 By Sarah Faulkner

capitol hill

Executives from U.S. drugmakers such as Regeneron Pharmaceuticals and Pfizer talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week. After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal […]

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc., Regeneron

Injectable Regeneron biologic therapy reduces triglycerides, cholesterol

November 15, 2016 By Sarah Faulkner

Regeneron

Researchers from the University of Pennsylvania presented preliminary data from a trial evaluating Regeneron Pharmaceutical‘s (NSDQ:REGN) injectable biologic drug therapy for reducing triglyceride levels. The team, led by Dr. Richard Dunbar, presented their work at the annual meeting of the American Heart Assn. The Phase I, placebo-controlled, double-blind study tested the safety and efficacy of Evinacumab, an […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Research & Development Tagged With: Regeneron

Regeneron boosts profits, misses revenue in Q3

November 4, 2016 By Sarah Faulkner

Regeneron

Shares in Regeneron (NSDQ:REGN) gained today after the biopharmaceutical company crushed earnings expectations on Wall Street with its 3rd-quarter results. The Tarrytown, N.Y.-based company posted profits of $264.8 million, or $2.27 per share, on sales of $1.22 billion for the 3 months ended Sept. 30, for bottom-line growth of 26% on sales growth of 7.3% compared with the […]

Filed Under: Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Regeneron

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS